Therefore, targeting PGC-1β and PGC-1α and rescuing the mitochondrial metabolic phenotype could be exploited as a therapeutic approach for the treatment of VHL-deficient renal carcinoma cells.74 Furthermore, a genomic study designed to assess the activity of ERRα in eight hundred breast tumor samples suggested that the molecular biology of PGC-1β in breast cancer progression relies on the c-Myc pathway. The gene discussed is PPARGC1B; the disease is breast carcinoma.